BCL2L1 and central nervous system cancer: WP1066 selectively inhibits the STAT3 pathway and reduces STAT3-driven expression of Bcl-2, Bcl-xL, and Mcl-1, triggering Bax activation [46] and resulting in extended survival of xenogeneic glioma mouse models [47].